Phase 1/2

Bavarian Nordic is leveraging its MVA-BN platform technology to advance its next generation of immuno-oncology candidates. The Company aims to activate a targeted immune response, arming the body’s own immune system to seek and destroy cancer cells. 

Providing the body with as many tools as possible significantly increases its chances to eradicate the disease. This tactic includes: priming antigen-specific T-cell activation; inducing T-cell expansion, migration and invasion into tumor sites; modifying tumor microenvironments to allow T-cell function and killing; induction of natural killer cells to account for tumor cells that cannot be recognized by T-cells; and overcoming T-cell inhibitory (checkpoint) signals. 

A tumor antibody enhanced therapeutic vaccine; TAEK-VAC is a novel immuno-oncology candidate employing our MVA-BN technology. A Phase 1/2 open label trial of intravenous administration of the vaccine, was initiated in 2021 in patients with advanced HER2 and brachyury-expressing cancers. The first stage of the trial is investigating the safety and tolerability of escalating doses of the vaccine before advancing into stage 2, expected in 2022.

Ongoing or planned trials

Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Location: USA
Read more: NCT04246671